What activities may incorporate risk mitigation in clinical trials?

Boost your GCP E6 (R3) exam readiness. Improve your understanding with engaging, insightful questions. Test yourself with hints and detailed explanations. Prepare effectively!

Multiple Choice

What activities may incorporate risk mitigation in clinical trials?

Risk mitigation in clinical trials is built into every stage of the study, starting with protocol design and continuing through implementation, monitoring, governance, and training. The best answer reflects this integrated, proactive approach: planning how the trial will be conducted to minimize risks, laying out how monitoring will detect issues, defining who is responsible for each aspect of safety and quality, and training staff so they can execute the plan competently. When these elements are in place, potential problems are identified early and addressed throughout the trial, helping protect participants and preserve data integrity. Post-trial data auditing alone happens after the fact and doesn’t prevent issues during the study. Focusing only on patient follow-up visits misses broader risk areas such as data quality, safety reporting, and governance. Relying solely on selecting an electronic data capture system overlooks the people, processes, and monitoring needed to manage risk across the trial.

Risk mitigation in clinical trials is built into every stage of the study, starting with protocol design and continuing through implementation, monitoring, governance, and training. The best answer reflects this integrated, proactive approach: planning how the trial will be conducted to minimize risks, laying out how monitoring will detect issues, defining who is responsible for each aspect of safety and quality, and training staff so they can execute the plan competently. When these elements are in place, potential problems are identified early and addressed throughout the trial, helping protect participants and preserve data integrity.

Post-trial data auditing alone happens after the fact and doesn’t prevent issues during the study. Focusing only on patient follow-up visits misses broader risk areas such as data quality, safety reporting, and governance. Relying solely on selecting an electronic data capture system overlooks the people, processes, and monitoring needed to manage risk across the trial.

More practice questions